In the opinion of most, precision medicine is the future of cancer therapeutics. By producing response rates well into double digits, and substantially extending progression-free and overall survival, the molecular testing of tumors to select optimal treatment may be a way to justify the high cost of new and emerging therapeutics. The road to this future will likely be long and winding, however, with a string of incremental successes amid inevitable disappointments. Our patients will walk this road with us, agreeing to testing and treatment when those tests come back positive for an eligible mutation.
Click on the PDF icon at the top of this introduction to read the full article.